During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.
ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p
Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si
At ASCO 2024 last month, editor-in-chief Jonah Comstock caught up with Dr Andree Amelsberg, SVP of global and US medical affairs at Eisai, to chat about what the company was sharing at the
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
